Iovance Biotherapeutics Inc
IOVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.4B
Close$
$-0.19
104.4% downside
Current Fair Value
104.4% downsideOvervalued by 104.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.40 Billion |
|---|---|
| Enterprise Value | $1.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.7 |
| Outstanding Shares | 418,511,000 |
Return
| Return on Equity | -49.03% |
|---|---|
| Return on Assets | -38.23% |
| Return on Invested Capital | -44.47% |
Valuation & Multiples
| P/E Ratio | -4.62 |
|---|---|
| PEG | 14.47 |
| Price to Sales | - |
| Price to Book Ratio | 4.44 |
| Enterprise Value to Revenue | 4.37 |
| Enterprise Value to EBIT | -3.53 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$81.13 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$87.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0658▲ 49.82% |
|---|---|
| Total Calls | 3,160,411▲ 9.03% |
| Total Puts | 3,368,407▲ 104.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 75.28%▲ 3.42% |
|---|---|
| Total Invested | $943.36M▲ 31.88% |
| Investors Holding | 300▲ 26.00% |
ESG Score
No data
About Iovance Biotherapeutics Inc
CEO: Maria Fardis